Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

Imaging for clinical trials

Pioneer of a new imaging diagnostic paradigm

We are transforming the imaging diagnostic world by developing the most accurate AI-powered digital biomarkers across multiple imaging modalities. Our focus is to achieve accurate early diagnosis to improve patient lives by helping radiologists and clinicians in their diagnostic workflow in oncology and metabolic diseases.


We deliver on a global scale

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.


Median's latest news

We were very pleased to welcome a large number of participants during our webcast held on October 25th, 2021. Fredrik Brag, CEO and founder of Median presented our company’s latest news and outlook and answered questions from the audience.  You didn’t have the opportunity to join? here is the replay! (in French)

Watch video

Latest press releases

21 October 2021

Median Technologies reports on its 2021 half-year results and its Q3 2021 business activity indicators 

Business continues to grow at a sustained pace in the first half of 2021 – Two highly impactful announcements for iBiopsy® and iCRO business units during Q3, 2021 -Third quarter revenue of €5.3m, up by 51% on the third quarter of 2020 – Cash and cash equivalents of €42.6m as of September 30th, 2021

16 September 2021

Median Technologies has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world, and selected to implement their clinical trial imaging strategy on some key oncology indications

This is the result of the renegotiation of terms of an existing Master Service Agreement (MSA) with this major big pharmaceutical company. The new scope of the MSA covers Phase III clinical trials for major indications in oncology and the terms are valid for 3 years. This partnership will contribute to sustain Median’s future bookings and revenues growth.

14 September 2021

Median Technologies changes the publication date of its H1 2021 results

Median Technologies (ALMDT: PA) will announce its H1 2021 results as well as its Q3 2021 business performance indicators on October 21, 2021 after trading close instead of October 14, 2021 after trading close.

6 September 2021

Median Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort

Median Technologies announces outstanding performance for its iBiopsy® Lung Cancer Screening CADx[1] to accurately characterize malignant vs benign lung nodules based on a large-scale patient cohort. Results show cutting-edge performance of 95.2% sensitivity and 95.7% specificity for lung nodule characterization that could significantly impact lung cancer screening programs adoption. The large-scale study is based on a cohort of 1,696 patients with a total of 15,608 lung nodules. Further results on a fully automated end-to-end lung cancer screening CADe/CADx including nodule detection and characterizationre expected in Q4, 2021.

29 July 2021

Median Technologies appoints Jean-Christophe Montigny as Chief Financial Officer and member of the Executive Committee

Median Technologies (ALMDT) today announces the appointment of Jean-Christophe Montigny as Chief Financial Officer. He will be a member of Median’s executive committee.


Our Autumn Corporate Newsletter

We are pleased to share with you our Autumn Corporate Newsletter, presenting our most recent announcements and what we did during the third quarter of 2021 and in early Q4. Click below to read the Newsletter!


NOV 23, 2021

Imaging in oncology trials: can it help to make “go or no go” decisions?

During our presentation, Labcorp and Median’s experts discuss modern imaging biomarkers covering the most important cancer hallmarks such as cell death, metabolism, vascularity, and hypoxia, and explain how they could be used in oncology trials for early response assessment and disease management.

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more


Enhancing imaging diagnostic accuracy

Our team of data scientists, AI engineers and clinicians is focused on developing the most accurate and cutting-edge AI-powered Software as a Medical Device (SaMD). iBiopsy® targets: lung cancer, liver cancer, and NASH to provide to patients an earlier and optimal diagnosis avoiding unnecessary invasive tests.

Read more


Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median